Prothena Corp Public (PRTA) Return on Capital Employed (2013 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Return on Capital Employed of 38.92% in Q1 2026, up 45.81% quarter-over-quarter from 71.82% in Q4 2025, and down 960.0% on a YoY basis from 4.53% in Q1 2025.
Prothena Corp Public (PRTA) Return on Capital Employed (2013 - 2026) Analysis & Trends
Prothena Corp Public's Return on Capital Employed history runs 14 years deep, the most recent figure standing at 38.92% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 960.0% year-over-year to 38.92%; the TTM figure through Mar 2026 stood at 38.92% (down 960.0% YoY), while the FY2025 annual figure was 54.19%, down 2722.0% from the prior year.
- Return on Capital Employed was 38.92% for Q1 2026 at Prothena Corp Public, up from 71.82% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11.83% in Q1 2022 to a low of 78.71% in Q3 2025.
- Historically, Return on Capital Employed has averaged 31.71% across 5 years, with a median of 29.3% in 2024.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed soared 4788 bps in 2022, then tumbled 5868 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 21.71% in 2022, then tumbled by 32 bps to 28.74% in 2023, then decreased by 3 bps to 29.57% in 2024, then plunged by 143 bps to 71.82% in 2025, then jumped by 46 bps to 38.92% in 2026.
- The last three Return on Capital Employed figures came in at 38.92% (Q1 2026), 71.82% (Q4 2025), and 78.71% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | -38.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.92% |
| Dec 31, 2025 | -71.82% |
| Sep 30, 2025 | -78.71% |
| Jun 30, 2025 | -74.23% |
| Mar 31, 2025 | -29.32% |
| Dec 31, 2024 | -29.57% |
| Sep 30, 2024 | -29.30% |
| Jun 30, 2024 | -15.55% |
| Mar 31, 2024 | -35.07% |
| Dec 31, 2023 | -28.74% |
| Sep 30, 2023 | -16.55% |
| Jun 30, 2023 | -26.27% |
| Mar 31, 2023 | -21.39% |
| Dec 31, 2022 | -21.71% |
| Sep 30, 2022 | -32.82% |
| Jun 30, 2022 | -0.96% |
| Mar 31, 2022 | 11.83% |
| Dec 31, 2021 | 12.25% |
| Sep 30, 2021 | 14.79% |
| Jun 30, 2021 | -18.39% |